MANHARD KIMBERLY
- SEC CIK
- 0001202094
Latest role at each company
- INBX Inhibrx Biosciences, Inc.Directoras of Sep 18, 2026
- CIK 0001739614Directoras of May 30, 2024
- HRTX HERON THERAPEUTICS, INC. /DE/EVP, Drug Developmentas of Apr 17, 2023
Trades
Every Form 4 that lists MANHARD KIMBERLY as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Company | Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| INBXInhibrx Biosciences, Inc. | Sep 15, 20265:52 PM ET | Sep 11 – Sep 15, 2026 | MANHARD KIMBERLYDirector | SSaleCommon Stock | −1.5K | $109.0283 | −$163.54K | 7.5K | −16.7% | SEC |
| INBXInhibrx Biosciences, Inc. | Sep 10, 20267:06 PM ET | Sep 8 – Sep 9, 2026 | MANHARD KIMBERLYDirector | SSaleCommon Stock | −1K | $115.4675 | −$115.47K | 9K | −10.0% | SEC |
| INBXInhibrx Biosciences, Inc. | Aug 30, 2024 | Aug 28, 2024 | MANHARD KIMBERLYDirector | PPurchaseCommon Stock | +10K | $13.98 | +$139.8K | 10K | New position | SEC |
| HRTXHERON THERAPEUTICS, INC. /DE/ | May 4, 2022 | May 3, 2022 | MANHARD KIMBERLYEVP, Drug Development | SSaleCommon Stock | −1.5K | $4.76 | −$7.16K | 10.87K | −12.2% | SEC |